Envision ALR Announces Rapid Screening for Swine Flu Using Nanotechnology Based Plastic Electronics
News May 05, 2009
Envision ALR has announced that it is commercializing a new form of nanotechnology based infectious disease detection system with the capability to distinguish between different flu strains within seconds.
The technology has already been shown to be effective in lab tests and the company is now accelerating the commercialization program.
Envision ALR CEO Wassim Mourtada explained from Abu Dhabi "Global pandemics, or even the fear of them have a severe economic impact. With current disease identification technologies requiring blood samples to be shipped to a laboratory for testing, distinguishing between pandemic strains and common ones can take up to twenty-four hours. Our technology has the potential to reduce this to under a minute, requires either a pin prick of blood or a salvia sample and will deliver the result of the diagnoses on the spot."
The technology is based on printed electronics, making use of the properties of a number of nanoparticle based inks and the hand held device is portable for use in doctors’ surgeries, hospitals or airports.
The system works for both bacterial and viral pathogens, and tests performed by the Naval Research Lab in Washington DC using Staphylococcus Enterotoxin B showed a two order of magnitude improvement over the current 'Lab Golden Standard' test.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE